FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Sanjay Gurunathan

Research Profile

Chemicals & Drugs

Procedures

Anatomy

T-Lymphocytes, Cytotoxic

Physiology

Concepts & Ideas

Co-author Network

Publications

TOP 3
Supachai Rerks-Ngarm; Merlin L Robb; Jim Tartaglia; Prasert Thongcharoen; Rapee Trichavaroj; Elizabeth Adams; Charla Andrews; Chureeratana Bowonwatanuwong; Supamit Chunsutthiwat; Nampueng Churikanont; Mark de Souza; Chirapa Eamsila; Jorge Flores; Donald Francis; Peter B Gilbert; Sanjay Gurunathan; Jaranit Kaewkungkal; Prayura Kunasol; Shuying S Li; Nelson L Michael; Chawetsan Namwat; Viseth Ngauy; Sorachai Nitayaphan; Robert J O'Connell; Robert M Paris; Nakorn Premsri; Jerome H Kim
Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E.
Merlin L Robb; Don Stablein; Jim Tartaglia; Prasert Thongcharoen; Prayura Kunasol; Nelson L Michael; Patricia Morgan; Sorachai Nitayaphan; Robert M Paris; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Elizabeth Adams; Michael Benenson; Joseph Chiu; Donald Francis; Peter Gilbert; Sanjay Gurunathan; Jaranit Kaewkungwal; Chirasak Khamboonruang; Jerome H Kim
Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.
Robert Paris; Punnee Pitisuttithum; Victoria R Polonis; Silvia Ratto-Kim; Anna Sambor; Henry A Stephens; Prasert Thongcharoen; Sasitorn Bejrachandra; Arthur E Brown; Mark de Souza; Donald Francis; Sanjay Gurunathan; Chitraporn Karnasuta; Jerome H Kim; Sorachai Nitayaphan
HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX(®) B/E.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Sanjay Gurunathan (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Supachai Rerks-Ngarm; Merlin L Robb; Jim Tartaglia; Prasert Thongcharoen; Rapee Trichavaroj; Elizabeth Adams; Charla Andrews; Chureeratana Bowonwatanuwong; Supamit Chunsutthiwat; Nampueng Churikanont; Mark de Souza; Chirapa Eamsila; Jorge Flores; Donald Francis; Peter B Gilbert; Sanjay Gurunathan; Jaranit Kaewkungkal; Prayura Kunasol; Shuying S Li; Nelson L Michael; Chawetsan Namwat; Viseth Ngauy; Sorachai Nitayaphan; Robert J O'Connell; Robert M Paris; Nakorn Premsri; Jerome H Kim
Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E.
The Journal of infectious diseases 2013;207(8):1195-205.
2012: Merlin L Robb; Don Stablein; Jim Tartaglia; Prasert Thongcharoen; Prayura Kunasol; Nelson L Michael; Patricia Morgan; Sorachai Nitayaphan; Robert M Paris; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Elizabeth Adams; Michael Benenson; Joseph Chiu; Donald Francis; Peter Gilbert; Sanjay Gurunathan; Jaranit Kaewkungwal; Chirasak Khamboonruang; Jerome H Kim
Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.
The Lancet infectious diseases 2012;12(7):531-7.
2012: Robert Paris; Punnee Pitisuttithum; Victoria R Polonis; Silvia Ratto-Kim; Anna Sambor; Henry A Stephens; Prasert Thongcharoen; Sasitorn Bejrachandra; Arthur E Brown; Mark de Souza; Donald Francis; Sanjay Gurunathan; Chitraporn Karnasuta; Jerome H Kim; Sorachai Nitayaphan
HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX(®) B/E.
Vaccine 2012;30(5):832-6.
2010: Andrew J Bett; Sheri A Dubey; Devan V Mehrotra; Liming Guan; Romnie Long; Kiersten Anderson; Kelly Collins; Christine Gaunt; Rose Fernandez; Suzanne Cole; Steve Meschino; Aimin Tang; Xiao Sun; Sanjay Gurunathan; Jim Tartaglia; Michael N Robertson; John W Shiver; Danilo R Casimiro
Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans.
Vaccine 2010;28(50):7881-9.
2009: Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Joseph Chiu; Robert Paris; Nakorn Premsri; Chawetsan Namwat; Mark de Souza; Elizabeth Adams; Michael Benenson; Sanjay Gurunathan; Jim Tartaglia; John G McNeil; Donald P Francis; Donald Stablein; Deborah L Birx; Supamit Chunsuttiwat; Chirasak Khamboonruang; Prasert Thongcharoen; Merlin L Robb; Nelson L Michael; Prayura Kunasol; Jerome H Kim
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.
The New England journal of medicine 2009;361(23):2209-20.
2007: Farley R Cleghorn; Jean W Pape; Mauro Schechter; Courtenay Bartholomew; Jorge Sanchez; Noreen Jack; Barbara J Metch; Marianne Hansen; Mary Allen; Huyen Cao; David C Montefiori; Georgia D Tomaras; Sanjay Gurunathan; Donna J Eastman; Regina F do Lago; Sonic Jean; Javier R Lama; Dale N Lawrence; Peter F Wright
Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120.
Journal of acquired immune deficiency syndromes (1999) 2007;46(2):222-30.
2007: Prasert Thongcharoen; Vinai Suriyanon; Robert M Paris; Chirasak Khamboonruang; Mark de Souza; Silvia Ratto-Kim; Chitraporn Karnasuta; Victoria R Polonis; Lynn Baglyos; Raphaelle El Habib; Sanjay Gurunathan; Susan Barnett; Arthur E Brown; Deborah L Birx; John G McNeil; Jerome H Kim
A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.
Journal of acquired immune deficiency syndromes (1999) 2007;46(1):48-55.
2007: Nina D Russell; Barney S Graham; Michael C Keefer; M Juliana McElrath; Steven G Self; Kent J Weinhold; David C Montefiori; Guido Ferrari; Helen Horton; Georgia D Tomaras; Sanjay Gurunathan; Lynn Baglyos; Sharon E Frey; Mark MULLIGAN; Clayton D Harro; Susan P Buchbinder; Lindsey R Baden; William A Blattner; Beryl A Koblin; Lawrence Corey
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial.
Journal of acquired immune deficiency syndromes (1999) 2007;44(2):203-12.
2006: Elizabeth J McFarland; Daniel C Johnson; Petronella Muresan; Terence Fenton; Georgia D Tomaras; James McNamara; Jennifer S Read; Steven D Douglas; Jaime G Deville; Marc Gurwith; Sanjay Gurunathan; John S Lambert
HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers.
AIDS (London, England) 2006;20(11):1481-9.
2005: Daniel C Johnson; Elizabeth J McFarland; Petronella Muresan; Terence Fenton; James McNamara; Jennifer S Read; Elizabeth Hawkins; Pamela L Bouquin; Scharla Estep; Georgia D Tomaras; Carol A Vincent; Mobeen H Rathore; Ann J Melvin; Sanjay Gurunathan; John Lambert
Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women.
The Journal of infectious diseases 2005;192(12):2129-33.
2005: Paul A Goepfert; Helen Horton; M Juliana McElrath; Sanjay Gurunathan; Guido Ferrari; Georgia D Tomaras; David C Montefiori; Mary Allen; Ya-Lin Chiu; Paul Spearman; Jonathan D Fuchs; Beryl A Koblin; William A Blattner; Sharon Frey; Michael C Keefer; Lindsey R Baden; Lawrence Corey
High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects.
The Journal of infectious diseases 2005;192(7):1249-59.
2005: Chitraporn Karnasuta; Robert M Paris; Josephine H Cox; Sorachai Nitayaphan; Punnee Pitisuttithum; Prasert Thongcharoen; Arthur E Brown; Sanjay Gurunathan; Jim Tartaglia; William L Heyward; John G McNeil; Deborah L Birx; Mark de Souza
Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand.
Vaccine 2005;23(19):2522-9.
2004: Danilo R Casimiro; Andrew J Bett; Tong-Ming Fu; Mary-Ellen Davies; Aimin Tang; Keith A Wilson; Minchun Chen; Romnie Long; Troy W McKelvey; Michael A Chastain; Sanjay Gurunathan; Jim Tartaglia; Emilio A Emini; John W Shiver
Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors.
Journal of virology 2004;78(20):11434-8.
2004: Robert M Paris; Sasitorn Bejrachandra; Chitraporn Karnasuta; Dasnayanee Chandanayingyong; Warunee Kunachiwa; Nipapan Leetrakool; S Prakalapakorn; Prasert Thongcharoen; S Nittayaphan; Punnee Pitisuttithum; Vinai Suriyanon; Sanjay Gurunathan; John G McNeil; Arthur E Brown; Deborah L Birx; Mark de Souza
HLA class I serotypes and cytotoxic T-lymphocyte responses among human immunodeficiency virus-1-uninfected Thai volunteers immunized with ALVAC-HIV in combination with monomeric gp120 or oligomeric gp160 protein boosting.
Tissue antigens 2004;64(3):251-6.
2004: Sorachai Nitayaphan; Punnee Pitisuttithum; Chitraporn Karnasuta; Chirapa Eamsila; Mark de Souza; Patricia Morgan; Victoria R Polonis; Michael W Benenson; Thomas C VanCott; Silvia Ratto-Kim; Jerome Kim; Darawan Thapinta; Robin P Garner; Valai Bussaratid; Pricha Singharaj; Raphaelle El Habib; Sanjay Gurunathan; William L Heyward; Deborah L Birx; John McNeil; Arthur E Brown
Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults.
The Journal of infectious diseases 2004;190(4):702-6.
2004: Genoveffa Franchini; Sanjay Gurunathan; Lynn Baglyos; Stanley Plotkin; Jim Tartaglia
Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors.
Expert review of vaccines 2004;3(4 Suppl):S75-88.
2004: Wannee Kantakamalakul; Mark de Souza; Chitraporn Karnasuta; Arthur Brown; Sanjay Gurunathan; Deborah L Birx; Prasert Thongcharoen; The Taveg
Enhanced sensitivity of detection of cytotoxic T lymphocyte responses to HIV type 1 proteins using an extended in vitro stimulation period for measuring effector function in volunteers enrolled in an ALVAC-HIV phase I/II prime boost vaccine trial in Thailand.
AIDS research and human retroviruses 2004;20(6):642-4.